

**JAY D. HORTON, M.D.**

**CURRICULUM VITAE**

**DATE & PLACE OF BIRTH**

February 25, 1962; Fairfield, IA

**PRESENT ADDRESS**

University of Texas Southwestern Medical Center  
Center for Human Nutrition  
Departments of Internal Medicine and Molecular Genetics  
5323 Harry Hines Blvd.  
Dallas, Texas 75390-9046

Telephone: (214) 648-9677  
FAX: (214) 648-8804  
E-mail: jay.horton@utsouthwestern.edu

**PROFESSIONAL TRAINING**

- |              |  |
|--------------|--|
| 1980-1984    | B.S., Zoology, University of Iowa, Iowa City, IA, with Honors and Distinction.   |
| 1984-1988    | M.D., University of Iowa College of Medicine, Iowa City, IA.   |
| 1988-1991    | Residency in Internal Medicine, University of Texas University of Texas Southwestern Medical Center at Dallas.   |
| 1991-1994    | Fellowship in Gastroenterology, University of Texas University of Texas Southwestern Medical Center at Dallas.   |
| 1994-1997    | Howard Hughes Postdoctoral Fellowship for Physicians, University of Texas Southwestern Medical Center at Dallas.   |
| 1997-2003    | Assistant Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas.   |
| 1999-2003    | Assistant Professor, Department of Molecular Genetics (secondary appointment), University of Texas Southwestern Medical Center at Dallas.  |
| 2003-2007    | Associate Professor, Departments of Internal Medicine and Molecular Genetics (secondary appointment), University of Texas Southwestern Medical Center at Dallas.   |
| 2007-Present | Professor and Dr. Robert C. Atkins and Veronica Atkins Chair in Obesity and Diabetes Research in the Departments of Internal Medicine and Molecular Genetics (secondary appointment), University of Texas Southwestern Medical Center at Dallas. |
| 2012-2013    | Interim Chief of Digestive and Liver Diseases, University of Texas Southwestern Medical Center at Dallas.  |
| 2013-2016    | Chief of Digestive and Liver Diseases, University of Texas Southwestern Medical Center at Dallas.  |
| 2015-Present | Director of the Center for Human Nutrition   |

# **Jay D. Horton, M.D.**

## **Curriculum Vitae**

### **EXAMINATIONS**

1988	Flex Exam
1991	American Board of Internal Medicine
1995, 2005, 2016	American Board of Gastroenterology

### **HONORS AND AWARDS**

1984	Honors Certificate of Achievement, University of Iowa
1983-1984	President's List
1982-1984	Dean's List
1981-1984	Scholastic Citation List for Honors Convocation
1982-1984	University of Iowa Honor Society Member
1999-2002	ADHF/AGA Industry Research Scholar Award
2000	NIH GMA 2 Study section (ad hoc)
2000-2004	American Heart Established Investigator
2000-2004	PEW Scholar
2002	NIH SSS-3 Study Section reviewer
2003	NIH Metabolism Study Section (ad hoc)
2003	Elected to American Society for Clinical Investigation
2003-2011	Consulting Editor for The Journal of Clinical Investigation
2003-Present	Consultant for Merck
2004-2008	Kern Aspen Lipid Conference Board Member
2004-2008	NIH Integrative Nutrition and Metabolic Processes Study Section
2004-2009	Consultant Metabasis Therapeutics
2005-2008	Consulting Editor for The Journal of Lipid Research
2005-2006	Consultant for Amgen
2005-Present	Consultant/SAB for Pfizer
2005	Consultant for Amgen
2005-2008	Reviewer for the AGA Industry Research Scholar Awards
2006-2023	Dr. Robert C. Atkins and Veronica Atkins Chair in Obesity and Diabetes Research
2006-2008	Scientific Advisory Board for Aegerion
2006	Organizer of the Kern Aspen Lipid Conference
2006	Consultant for Lilly
2006	Consultant for Alnylam
2006	Consultant for BMS
2006	Consultant for Regeneron
2006-2007	Consultant for Novartis
2007	Consultant for Schering-Plough
2007	Recipient of the University of Iowa Carver College of Medicine's Distinguished Alumnus Award for Early Career Achievement
2008	Consultant for Genentech
2008	Elected to Association of American Physicians
2008-2023	Associate Editor of The Journal of Lipid Research
2009	Organizer of the Deuel Lipid Conference
2009	Consultant for Regeneron

## **Jay D. Horton, M.D.**

### **Curriculum Vitae**

- 2010 NIH Special Emphasis Panel ZRG1 EMNR-B  
2008-2014 AHA Irvine H. Page Young Investigator Research Award Selection Committee, Chair 2010-2012  
2011 Fellow of the American College of Physicians  
2012 NIH Nutrition Obesity Research Centers (P30)  
2012 NIH Special Emphasis Panel ZRG1 EMNR-E  
2012-Present Associate Editor for Arteriosclerosis, Thrombosis, and Vascular Biology  
2012 ATVB Special Recognition Award in Arteriosclerosis  
2013 Scientific Advisory Board, Catabasis  
2015 Co-Organizer of Keystone Meeting: Metabolic Syndrome: Mitochondria and Energy Expenditure/Liver Metabolism and Nonalcoholic Fatty Liver Disease  
2015 NIH Special Emphasis Panel/Scientific Review Group 2015/10 ZDK1 GRB-9  
2015-2018 ASCI Council Member  
2015-Present Distinguished Chair in Human Nutrition  
2015-Present The Scott Grundy Director's Chair  
2016 American Association of Clinical Endocrinologists Frontiers in Science Award  
2017 NIH INMP Study Section-ad hoc  
2020 NIH INMP Study Section-ad hoc  
2020 Organizer of the Deuel Lipid Conference  
2020-2024 NIH, Board of Scientific Counselors, National Institute of Diabetes, Digestive and Kidney Diseases  
2022-present Consultant for Regeneron  
2022-2024 NIH, Chair of Board of Scientific Counselors, National Institute of Diabetes, Digestive and Kidney Diseases

### **INVITED PRESENTATIONS**

- 1999 European Atherosclerosis Society Meeting and KOS Satellite Conference, Athens, Greece  
1999 Glaxo Wellcome, Research Triangle Park, NC  
2000 Deuel Lipid Conference, Stevenson, WA  
2000 Gordon Conference, Lipoprotein Metabolism, Meriden, NH  
2000 Kern Aspen Lipid Conference, Aspen, CO  
2000 Dept. of Biochemistry, University of Minnesota, Minneapolis, MN  
2000 Parke-Davis, Ann Arbor, MI  
2000 HDL Consultation Meeting, Paris, France. Pfizer.  
2001 Affymetrix, Santa Clara, CA  
2001 VISN 17 Research Conference, Dallas VA Medical Center  
2001 Lynx Inc., Haywood, CA  
2001 Dept. of Pathology, Wake Forest School of Medicine, Winston-Salem, NC  
2001 Dept. of Biochemistry, University of Wisconsin, Madison, WI  
2001 Banting and Best Diabetes Centre, University of Toronto, Toronto, Canada  
2001 Obesity and CVD Working Group Meeting, NIH, Bethesda, MD  
2001 Division of Endocrinology, Washington University, St. Louis, MO  
2001 Division of Endocrinology, Baylor College of Medicine, Houston, TX

**Jay D. Horton, M.D.****Curriculum Vitae**

- 2002 Dept. of Physiology, University of Massachusetts, Worcester, MA  
2002 Dept. of Molecular and Cellular Physiology, LSU, Shreveport, LA  
2002 Suntory Pharmaceutical Research Laboratories, Cambridge, MA  
2002 Symposium and Training X: Understanding Metabolism in the Mouse, Rogers NMR, Dept. Radiology, UT Southwestern Medical Center  
2002 Biochemical Society Meeting No. 667, Cardiff University, Cardiff, Wales  
2002 67<sup>th</sup> Cold Spring Harbor Symposium on Quantitative Biology: The Cardiovascular System, Cold Springs Harbor, NY  
2003 FASEB: Molecular Biology of Intestinal Lipid Transport and Metabolism, Snow Mass, CO  
2003 European Lipoprotein Club, Keynote, Tutzing, Germany  
2003 Nobel Conference “Transcriptional control of lipid homeostasis”, Stockholm, Sweden  
2003 Bay Area Lipid Club, San Francisco, CA  
2004 Pennington Symposium, “Pathogenesis of the Metabolic Syndrome,” Baton Rouge, LA  
2004 5<sup>th</sup> Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, Co-Chair and Speaker in Lipid Trafficking Session, San Francisco, CA  
2004 Endocrinology Grand Rounds, University of Colorado, Denver, CO  
2004 Gordon Conference, Lipoprotein Metabolism, Meriden, NH  
2004 AASLD Basic Science Workshop, “Liver, Lipids and Lipotoxicity,” Boston MA  
2004 Merck & Co. Keynote speaker atherosclerosis division retreat.  
2005 American Society of Nephrology, “Nuclear Receptors and our Craving for More Sugar and Fat,” Philadelphia, PA  
2005 AASLD Focus Study Group 2, “Interactions of Statin Drugs with NAFLD: Risk or benefit or neither,” San Francisco, CA  
2005 American Gastroenterological Association Clinical Congress, “Pathogenic Mechanisms of NAFLD,” Hollywood, FL  
2006 George Washington University, Cardiology Grand Rounds  
2006 University of Alabama, Nutrition Center Grand Rounds  
2006 Avison Biomedical Symposium, Yonsei University College of Medicine, Seoul, Korea  
2006 Distinguished Scientist Seminar, University of South Alabama  
2006 Endocrinology Grand Rounds, UT San Antonio  
2006 FASEB: Molecular Biology of Intestinal Lipid Transport and Metabolism, Tucson, AZ  
2006 Gordon Conference on Lipoprotein Metabolism, South Hadley, MA  
2006 AASLD Clinical Research Single Topic Conference: Alcoholic and Non-Alcoholic Steatohepatitis. Atlanta, Georgia  
2006 NIH NIDDK Workshop on Lipodystrophy, Bethesda, MD  
2006 International Symposium on Lipoprotein Receptors: From Cell Biology to Disease, Santiago, Chile  
2007 Keystone Symposium on Metabolic Syndrome and Cardiovascular Risk, Steamboat Springs, CO  
2007 Gordon Conference on Molecular and Cellular Biology of Lipids, Waterville Valley Resort, NH  
2007 Kern Aspen Lipid Conference, Aspen, CO  
2007 BioSymposia, Disorders of Lipid Metabolism, San Diego, CA

**Jay D. Horton, M.D.****Curriculum Vitae**

- 2007 Endocrinology Grand Rounds, University of Colorado, Denver, CO  
2008 Gordon Conference: Plasminogen Activation & Extracellular Proteolysis, Ventura  
Harbortown Resort, CA  
2008 Deuel Conference on Lipids, Coronado, CA  
2008 American Diabetes Association 68<sup>th</sup> Scientific Session, San Francisco, CA  
2008 Gordon Conference: Proprotein Processing, Trafficking & Secretion, Colby-  
Sawyer College in New London, NH  
2008 Gordon Conference: Lipoprotein Metabolism, Waterville Valley, NH  
2008 Gordon Conference: Proteolytic Enzymes & Their Inhibitors, Colby-Sawyer  
College in New London, NH  
2008 3<sup>rd</sup> Annual NLA Masters Summit, AHA Meeting, New Orleans, LA  
2009 Keystone Symposium on Type 2 Diabetes and Insulin Resistance/Obesity: Novel  
Aspects of Regulation of Body Weight. Banff Springs, Banff, Canada  
2009 JLR 50<sup>th</sup> Anniversary Lecture at ATVB Meeting, Washington D.C.  
2009 Obesity and Fatty Liver Disease, Digestive Disease Week 2009 in Chicago, IL  
2009 Gordon Conference on Molecular and Cellular Biology of Lipids, Waterville  
Valley Resort, NH  
2009 Falk Symposium: Liver and Metabolic Syndrome. Hannover, Germany  
2009 Annual International Conference of Korean Society of Medical Biochemistry and  
Molecular Biology. Plenary Lecture. Seoul, Korea  
2009 UT Southwestern University Lecture  
2010 Gordon Conference: Lipoprotein Metabolism, Waterville Valley, NH  
2011 UT Southwestern President's Lecture  
2011 LIPID MAPS Annual Meeting: Lipidomics Impact on Cell Biology, Cancer, and  
Metabolic Diseases  
2011 34th Steenbock Symposium, Madison, WI  
2012 Deuel Conference on Lipids, Palm Springs, CA  
2012 The Academy of Medicine, Engineering and Sciences of Texas, Houston, TX  
2012 International Biosciences of Lipids, Banff, Alberta, Canada  
2012 5<sup>th</sup> Annual Diabetes Conference of Wisconsin, Milwaukee, WI  
2012 Banting and Best Diabetes Centre, University of Toronto, Toronto, Canada  
2013 New York Lipid Club, New York, NY  
2013 Internal Medicine Grand Rounds, Columbia University, New York, NY  
2013 Endocrinology Grand Rounds, Columbia University, New York, NY  
2013 Kern Lipid Conference, Vail, CO  
2013 Endocrinology Grand Rounds, Beth Israel Hospital, Harvard Medical School,  
Boston, MA  
2013 Liver Center Seminar Speaker, UCSF, San Francisco, CA  
2013 AHA Scientific Sessions, Dallas, TX  
2013 Diabetes Center Lecture, University of Chicago, Chicago, IL  
2013 Cardiology Grand Rounds, Northwestern University, Chicago, IL  
2014 Deuel Conference on Lipids, The Francis Simon Lecture San Diego, CA  
2014 Digestive Disease Week, The Dr. Charles S. Lieber Lecture, Chicago, IL  
2014 Gordon Conference: Lipoprotein Metabolism, Waterville Valley, NH  
2014 FASEB: Nutrient Sensing and Metabolic Signaling, Big Sky, MT  
2014 AHA Scientific Sessions, Chicago, IL  
2014 Keystone Meeting: Lipid Pathways, Dublin Ireland  
2014 World Congress of Cardiology, Melbourne, Australia

**Jay D. Horton, M.D.****Curriculum Vitae**

- 2014 The 9<sup>th</sup> Metabolic Syndrome Type 2 Diabetes and Atherosclerosis Congress (MSDA2014), Kyoto, Japan
- 2014 Annual Meeting of the Society of Cell Biology, Puerto Varas, Chile
- 2015 Cold Spring Harbor Asia on Lipid Metabolism and Metabolic Disorders, Suzhou, China
- 2015 Tsinghua University, Beijing, China
- 2015 Lilly China Research and Development Center, Shanghai, China
- 2015 UK Association for Clinical Biochemistry and Laboratory Medicine International Lecturer, Cardiff, Wales
- 2015 Keystone Meeting: Metabolic Syndrome: Mitochondria and Energy Expenditure / Liver Metabolism and Nonalcoholic Fatty Liver Disease. Whistler, BC, Canada
- 2015 Vanderbilt Institute of Chemical Biology, Nashville, TN
- 2015 University of Alberta, Edmonton, Alberta, Canada
- 2015 Rubinstein Lectureship, Canadian Lipoprotein Conference, Toronto, Ontario, Canada
- 2015 AHA ATVB/PVD Invited Speaker and Session Chair, San Francisco, CA
- 2016 Vanderbilt Gastroenterology Center Grand Rounds, Nashville, TN
- 2016 ASBMB EXPERIMENTAL BIOLOGY 2016, San Diego CA
- 2016 American Association of Clinical Endocrinologists Frontiers in Science Award Lecture, Orlando, FL
- 2016 ADA, New Orleans, LA
- 2016 FASEB Scientific Conference "Lipid Droplets: Dynamic Organelles in Metabolism and Beyond," Snowmass, CO
- 2016 Kern Lipid Conference, Vail, CO
- 2016 GI Grand Rounds, USC, Los Angeles, CA
- 2016 GI Grand Rounds, University of Pennsylvania, Philadelphia, PA
- 2016 Yale ICSNM Program, New Haven, CT
- 2017 The Ramanbhai Foundation 8<sup>th</sup> International Symposium: Advances in New Drug Discovery & Development. Ahmedabad, India
- 2017 Medical Grand Rounds-Priscilla White Lectureship at the Brigham and Women's Hospital, Boston, MA
- 2017 The Priscilla White Annual Lecture on Metabolism, Joslin Diabetes Center, Boston, MA
- 2017 Cold Spring Harbor Conferences Asia: Lipid Metabolism & Metabolic Disorders, Suzhou, China
- 2017 European Atherosclerosis Society, Prague, Czech Republic
- 2017 58<sup>th</sup> International Conference on the Bioscience of Lipids (ICBL), Zurich, Switzerland
- 2017 Wuhan International Symposium on Lipid Metabolism and Disease, Wuhan, China
- 2017 International Symposium of Genetics and Human Phonomics, Fudan University, Shanghai, China
- 2017 First Annual Conference of Clinical Rare Metabolic Disease Subsociety of the Biophysical Society of China, Nanjing, China
- 2017 DeWitt Goodman Seminar, Columbia University, New York, NY
- 2018 Second Annual Conference of the Chinese Society for Lipid Metabolism and Bioenergetics, Shanghai, China

**Jay D. Horton, M.D.**  
**Curriculum Vitae**

- 2018 The Second Annual Conference of Clinical Rare Metabolic Disease Subsociety of the Biophysical Society of China, Nanjing, China  
2018 Lunenfeld-Tanenbaum International Research Symposium, Toronto, Canada  
2018 FASEB Scientific Conference "Nutrient Sensing and Metabolic Signaling," Snowmass, CO  
2018 Kern Lipid Conference, Vail, CO  
2018 16<sup>th</sup> Annual Biophysics Congress, Chengdu, China  
2018 Chilean Society of Physiological Sciences (SChCF) Annual Meeting, Huilo-Huilo Ecological Reserve, Chile  
2018 Keynote speaker at annual postdoctoral symposium hosted by DUNES (Duke-NUS Early Career Scientists association) at Duke-NUS, Singapore  
2018 Keynote speaker at UCLA third annual Cardiovascular Symposium, Los Angeles, CA  
2018 Keynote speaker at NHLBI Working Group (WG), entitled "Hypertension: Barriers to Translation" Bethesda, MD  
2019 Northwestern GI/Liver Grand Rounds, Chicago, IL  
2019 Keynote Speaker at 2019 Fudan Forum on Liver Disease and Metabolism, Shanghai, China  
2019 European Atherosclerosis Society, Maastricht, Netherlands  
2019 5th Annual Conference of Chinese Stroke Association (CSA) & Tiantan International Stroke Conference 2019 (TISC 2019), Beijing, China  
2019 University of Iowa, Frontiers in Obesity, Diabetes and Metabolism, Iowa City, IA  
2019 Alcoholic and Nonalcoholic Steatohepatitis: Pathogenesis and Mechanisms of Liver Injury Joint NIAAA-NIDDK Research Workshop, Bethesda, MD  
2020 University of Oklahoma, Harold Hamm Diabetes Center 17<sup>th</sup> Annual Research Symposium  
2021 Keystone Meeting: Fatty Liver Disease and Multi-System Complications. Organizer and speaker. Virtual  
2022 Korean Endocrinology Society, Seoul, Korea  
2022 ADA Meeting, New Orleans, LA  
2022 Kern Lipid Conference, Vail, CO  
2022 Endocrinology Grans Rounds, Johns Hopkins, Virtual  
2023 Endocrinology Grand Rounds, Beth Israel Deaconess, Harvard, Virtual  
2023 Havel Lecture, Deuel Conference, Dana Point, CA  
2023 Distinguished Scientist Seminar Series, Georgetown University, Washington D.C.  
2023 European Atherosclerosis Society, Mannheim, Germany  
2023 Keynote Speaker at University of Pennsylvania' Nutrition and Obesity Symposium, Philadelphia, PA  
2024 NASH-TAG 2024 Conference, Park City, UT  
2024 World Heart Federation Conference, Shanghai, China  
2024 6th MHRC Symposium at SIMS, Buyeo, South Korea

**RESEARCH**

- 1981-1984 Undergraduate Honors Research Project with Jane Hayes, Ph.D. Department of Zoology, University of Iowa. "Genetic Analysis of Diapause in the Milkweed Bug Oncopeltus fasciatus"

## **Jay D. Horton, M.D.**

### **Curriculum Vitae**

- 1985 Student Research Fellowship with Martin Sokoll, M.D. Department of Anesthesia, University of Iowa. "Effects of Succinylcholine Chloride on the Response of Fast and Slow Muscle in the Rabbit"
- 1987 Senior Honors Research Project with Jeffrey Field, M.D. Division of Gastroenterology, University of Iowa. "Effects of HMG-CoA Reductase Inhibition on Lipoprotein Secretion in Caco-2 Cultured Cells"
- 1991-1993 NIH Gastroenterology Research Fellowship with David Spady, M.D. and Jennifer Cuthbert, M.D. Division of Gastroenterology, University of Texas Southwestern Medical Center at Dallas
- 1994- 1997 Howard Hughes Postdoctoral Research Fellowship for Physicians with Joseph L. Goldstein, M.D. and Michael S. Brown, M.D. Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas. "In Vivo Role of Transcription Factors for the LDL Receptor"

### **PUBLICATIONS**

1. J.D. Horton, J.A. Cuthbert and D.K. Spady. 1993. Dietary fatty acids regulate hepatic LDL transport by altering LDL receptor protein and mRNA levels. *J. Clin. Invest.* 92:743-749.
2. J.D. Horton, J.A. Cuthbert and D.K. Spady. 1994. Regulation of 7 $\alpha$ -hydroxylase by dietary psyllium in the hamster. *J. Clin. Invest.* 93:2084-2092.
3. J.D. Horton, J.A. Cuthbert and D.K. Spady. 1995. Regulation of hepatic 7 $\alpha$ -hydroxylase expression and response to dietary cholesterol in the rat and hamster. *J. Biol. Chem.* 270:5381-5387.
4. D.K. Spady, J.D. Horton and J.A. Cuthbert. 1995. Regulatory effects of n-3 polyunsaturated fatty acids on hepatic LDL uptake in the hamster and rat. *J. Lipid Res.* 36:1009-1020.
5. T.E. Willnow, A. Rohlmann, J.D. Horton, H. Otani, J.R. Braun, R.E. Hammer and J. Herz. 1996. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. *EMBO J.* 15:2632-2639.
6. H. Shimano\*, J.D. Horton\*, R.E. Hammer, I. Shimomura, M.S. Brown and J.L. Goldstein. 1996. Overproduction of cholesterol and fatty acids causing marked liver enlargement in transgenic mice expressing truncated SREBP-1a. *J. Clin. Invest.* 98:1575-1584. \* The first two authors contributed equally to this work.
7. I. Shimomura, H. Shimano, J.D. Horton, J.L. Goldstein and M.S. Brown. 1997. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. *J. Clin. Invest.* 99:838-845.
8. H. Shimano, J.D. Horton, I. Shimomura, R.E. Hammer, M.S. Brown and J.L. Goldstein. 1997. Isoform 1c of sterol regulatory element binding protein is less

**Jay D. Horton, M.D.**  
**Curriculum Vitae**

- active than isoform 1a in livers of transgenic mice and in cultured cells. *J. Clin. Invest.* 99:846-854.
9. H. Shimano, I. Shimomura, R.E. Hammer, J. Herz, J.L. Goldstein, M.S. Brown and J.D. Horton. 1997. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. *J. Clin. Invest.* 100:2115-2124.
  10. I. Shimomura, Y. Bashmakov, H. Shimano, J.D. Horton, J.L. Goldstein and M.S. Brown. 1997. Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver. *Proc. Natl. Acad. Sci. USA.* 94:12354-12359.
  11. J.D. Horton, Y. Bashmakov, I. Shimomura and H. Shimano. 1998. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. *Proc. Natl. Acad. Sci. USA.* 95:5987-5992.
  12. J.D. Horton, I. Shimomura, M.S. Brown, R.E. Hammer, J.L. Goldstein and H. Shimano. 1998. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. *J. Clin. Invest.* 101:2331-2339.
  13. I. Shimomura, H. Shimano, B.S. Korn, Y. Bashmakov and J.D. Horton. 1998. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. *J. Biol. Chem.* 273:35299-35306.
  14. B.S. Korn, I. Shimomura, Y. Bashmakov, R.E. Hammer, J.D. Horton, J.L. Goldstein and M.S. Brown. 1998. Blunted feedback suppression of SREBP processing by dietary cholesterol in transgenic mice expressing sterol-resistant SCAP(D443N). *J. Clin. Invest.* 102:2050-2060.
  15. J.D. Horton, H. Shimano, R.L. Hamilton, M.S. Brown and J.L. Goldstein. 1999. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. *J. Clin. Invest.* 103:1067-1076.
  16. I. Shimomura, Y. Bashmakov and J.D. Horton. 1999. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. *J. Biol. Chem.* 274:30028-30032.
  17. I. Shimomura, Y. Bashmakov, S. Ikemoto, J.D. Horton, M.S. Brown and J.L. Goldstein. 1999. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. *Proc. Natl. Acad. Sci. USA.* 96:13656-13661.

**Jay D. Horton, M.D.****Curriculum Vitae**

18. S. Sebastian, J.D. Horton and J.E. Wilson. 2000. Anabolic function of the type II isozyme of hexokinase lipid synthesis. *Biochem. Biophys. Res. Commun.* 270:886-891.
19. J.J. Repa, E.G. Lund, J.D. Horton, E. Leitersdorf, D.W. Russell, J.M. Dietschy and S.D. Turley. 2000. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia: reversal by cholic acid feeding. *J. Biol. Chem.* 275:39685-39692.
20. J. Zhang, J. Ou, Y. Bashmakov, J.D. Horton, M.S. Brown and J.L. Goldstein. 2001. Insulin blocks transcription of IRS-2 gene in rat liver through an insulin response element (IRE) that resembles the IREs of other insulin-repressed genes. *Proc. Natl. Acad. Sci. USA.* 96:3756-3761.
21. M. Matsuda, B.S. Korn, R.E. Hammer, Y-A. Moon, R. Komuro, J.D. Horton, J.L. Goldstein, M.S. Brown and I. Shimomura. 2001. SREBP cleavage-activating protein (SCAP) is required for hepatic response to cholesterol deprivation and to insulin elevation. *Genes Dev.* 15:1206-1216.
22. Y-A. Moon, N.A. Shah, S. Mohapatra, J.A. Warrington and J.D. Horton. 2001. Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. *J. Biol. Chem.* 276:45358-45366.
23. J. Yang, J.L. Goldstein, R.E. Hammer, Y-A. Moon, M.S. Brown and J.D. Horton. 2001. Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. *Proc. Natl. Acad. Sci. USA.* 98:13607-13612.
24. G. Liang, J. Yang, J.D. Horton, R.E. Hammer, J.L. Goldstein and M.S. Brown. 2002. Diminished hepatic response to fasting/refeeding and LXR agonists in mice with selective deficiency of SREBP-1c. *J. Biol. Chem.* 277:9520-9528.
25. C. Vasandani, A.I. Kafrouni, Y. Bashmakov, M. Gotthardt, J.D. Horton and D.K. Spady. 2002. Upregulation of hepatic LDL transport by n-3 fatty acids in LDL receptor knockout mice. *J. Lipid Res.* 43:772-784.
26. L. Yu, J. Li-Hawkins, R.E. Hammer, K.E. Berge, J.D. Horton, J.C. Cohen and H.H. Hobbs. 2002. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces absorption of dietary cholesterol. *J. Clin. Invest.* 110:671-680.
27. Y-A. Moon and J.D. Horton. 2003. Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. *J. Biol. Chem.* 278:7335-7343.
28. J.D. Horton, I. Shimomura, S. Ikemoto, Y. Bashmakov, and R.E. Hammer. 2003. Overexpression of SREBP-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. *J. Biol. Chem.* 278:36652-36660.

**Jay D. Horton, M.D.**  
**Curriculum Vitae**

29. J.D. Horton, N.A. Shah, J.A. Warrington, N.N. Anderson, S.W. Park, M.S. Brown, and J.L. Goldstein. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. *Proc. Natl. Acad. Sci. USA.* 100:12027-12032.
30. A.P. Beigneux, C. Kosinski, B. Gavino, J.D. Horton, W.C. Skarnes, and S.G. Young. 2004. ATP-citrate lyase deficiency in the mouse. *J. Biol. Chem.* 279: 9557-9564.
31. L.J. Engelking, H. Kuriyama, R.E. Hammer, J.D. Horton, M.S. Brown, J.L. Goldstein, and G. Liang. 2004. Overexpression of human Insig-1 in livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. *J. Clin. Invest.* 113:1168-1175.
32. K. Iizuka, R.K. Bruick, G. Liang, J.D. Horton, and K. Uyeda. 2004. Deficiency of carbohydrate response element binding protein (ChREBP) reduces lipogenesis as well as glycolysis. *Proc. Natl. Acad. Sci. USA.* 101: 7281-7286.
33. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, J.C. Cohen, S.M. Grundy and H.H. Hobbs. 2004. Prevalence of hepatic steatosis in a large U.S. population: Impact of ethnicity. *Hepatology*. 40:1387-1395.
34. S.W. Park, Y.-A. Moon, J.D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. 2004. *J. Biol. Chem.* 279:50630-50638.
35. H. Kuriyama, G. Liang, L.J. Engelking, J.D. Horton, J.L. Goldstein, and M.S. Brown. 2005. Compensatory increase in fatty acid synthesis in adipose tissue of mice with conditional deficiency of SCAP in liver. *Cell Metab.* 1:41-51.
36. N.Y. Kalaany, K.C. Gauthier, A.M. Zavacki, P.P.A. Mammen, T. Kitazume, J.A. Peterson, J.D. Horton, D.J. Garry, A.C. Bianco, and D.J. Mangelsdorf. 2005. LXR $\alpha$ s regulate the balance between fat storage and oxidation. *Cell Metab.* 1:231-244.
37. S. Rashid, D.E. Curtis, R. Garuti, N.N. Anderson, Y. Bashmakov, Y.K. Ho, R.E. Hammer, Y.-A. Moon, and J.D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking *Pcsk9*. *Proc. Natl. Acad. Sci. USA.* 102:5374-5379.
38. E.P. Beltroy, J.A. Richardson, J.D. Horton, S.D. Turley, and J.M. Dietschy. 2005. Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease. *Hepatology*. 42:886-893.
39. L.J. Engelking, G. Liang, R.E. Hammer, K. Takaishi, H. Kuriyama, B.M. Evers, W-P. Li, J.D. Horton, J.L. Goldstein, M.S. Brown. 2005. Schoenheimer effect

**Jay D. Horton, M.D.**  
**Curriculum Vitae**

- explained-Feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. *J. Clin. Invest.* 115: 2489-2498.
40. M. Yi, J.D. Horton, J.C. Cohen, H.H. Hobbs, R.M. Stephens. 2006. WholePathwayScope: A comprehensive pathway-based analysis tool for high-throughput data. *BMC Bioinformatics*. 7:30.
41. Z. Zhao, Y. Tuakli-Wosornu, T.A. Lagace, L. Kinch, N.V. Grishin, J.D. Horton, J.C. Cohen, and H.H. Hobbs. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. *Am. J. Hum. Genet.* 79:514-523.
42. T.A. Lagace, D.E. Curtis, R. Garuti, M.C. McNutt, S.W. Park, H.B. Prather, N. N. Anderson, Y.K. Ho, R.E. Hammer, and J.D. Horton. 2006. Secreted PCSK9 decreases LDL receptors in hepatocytes and livers of parabiotic mice. *J. Clin. Invest.* 116:2995-3005.
43. D-W. Zhang, T.A. Lagace, R. Garuti, Z. Zhao, M. McDonald, J.D. Horton, J.C. Cohen, and H.H. Hobbs. 2007. Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation. *J. Biol. Chem.* 282:20502-20512.
44. M.C. McNutt, T.A. Lagace, and J.D. Horton. 2007. Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells. *J. Biol. Chem.* 282:20799-20803.
45. M. John, R. Constien, A. Akinc, M. Goldberg, Y-A. Moon, M. Spranger, P. Hadwiger, J. Soutschek, H.P. Vornlocher, M. Manoharan, M. Stoffel, R. Langer, D.G. Anderson, J.D. Horton, V. Koteniansky, and D. Bumcrot. 2007. Effective RNAi-mediated gene silencing without interruption of the endogenous miRNA pathway. *Nature*. 449:745-746.
46. H-J. Kwon, T.A. Lagace, M.C. McNutt, J.D. Horton, and J. Deisenhofer. 2008. Molecular basis for LDL receptor recognition by PCSK9. *Proc. Natl. Acad. Sci. USA*. 105: 1820-1825. PMCID: PMC2538846.
47. A. Grefhorst, M.C. McNutt, T.A. Lagace, and J.D. Horton. 2008. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. *J. Lipid Res.* 49: 1303-1311. PMCID: PMC2386900.
48. K. Minehira, S.G. Young, C.J. Villanueva, L. Yetukuri, M. Oresic, M.K. Hellerstein, R.V. Farese Jr., J.D. Horton, F. Preitner, B. Thorens, L. Tappy. 2008. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. *J. Lipid Res.* 49:2038-2044. PMCID PMC3837456.
49. M. Frank-Kamenetsky, A. Grefhorst, N.N. Anderson, T.S. Racie, B. Bramlage, A. Akinc, D. Butler, K. Charisse, R. Dorkin, Y. Fan, C. Gamba-Vitalo, P.

**Jay D. Horton, M.D.****Curriculum Vitae**

- Hadwiger, M. Jayaraman, M. John, K.N. Jayaprakash, M. Maier, K. Nechev, T. Rajeev, I. Read, J. Röhl, J. Soutschek, P. Tan, J. Wong, G. Wang, T. Zimmermann, A. de Fougerolles, H-P. Vornlocher, R. Langer, D.G. Anderson, M. Manoharan, V. Koteliansky, J.D. Horton, and K. Fitzgerald. 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in NHP. *Proc. Natl. Acad. Sci. USA.* 105:11915-11920. PMCID: PMC2575310.
50. Y-A Moon, R.E. Hammer, and J.D. Horton. 2009. Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. *J. Lipid Res.* 50:412-423. PMCID: PMC2638104.
51. V.A. Cortés, D.E. Curtis, S. Sukumaran, X. Shao, V. Parameswara, S. Rashid, A.R. Smith, J. Ren, V. Esser, R. E. Hammer, A.K. Agarwal, J.D. Horton, and A. Garg. 2009. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2 deficient mouse model of congenital generalized lipodystrophy. *Cell Metab.* 9:165-176. PMCID: PMC2673980.
52. M.C. McNutt, H-J. Kwon, C. Chen, J.R. Chen, J.D. Horton, and T.A. Lagace. 2009. Antagonism of secreted PCSK9 increases low-density lipoprotein receptor expression in HepG2 cells. *J. Biol. Chem.* 284:10561-10570. PMCID: PMC2701207.
53. S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, and H.H. Hobbs. 2009. Genetic and metabolic determinants of plasma PCSK9 levels. *J. Clin. Endocrinol. Metab.* 94:2537-2543. PMCID: PMC2708952.
54. C-W. Kim, Y-A. Moon, S.W. Park, D. Cheng, H. J. Kwon, and J.D. Horton. 2010. Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis. *Proc. Natl. Acad. Sci. USA.* 107:9626-9631. PMCID: PMC2906888.
55. M. Kars, L. Yang, M.F. Gregor, B.S. Mohammed, T.A. Pietka, B.N. Finck, B.W. Patterson, J.D. Horton, B. Mittendorfer, G.S. Hotamisligil, and S. Klein. 2010. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. *Diabetes.* 59:1899-1905. PMCID: PMC2911053.
56. J.D. Browning and J.D. Horton. 2010. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. *J. Lipid Res.* 51:3359-3363. PMCID: PMC2952577.
57. C. Colbert, C-W. Kim, Y-A. Moon, L. Henry, M. Palnitkar, W.B. McKean, K. Fitzgerald, J. Deisenhofer, J.D. Horton, and H.J. Kwon. 2010. The crystal structure of Spot14, a modulator of fatty acid synthesis. *Proc. Natl. Acad. Sci. USA.* 107:18820-18825. PMCID: PMC2973905

**Jay D. Horton, M.D.****Curriculum Vitae**

58. Y.S. Jeong D. Kim, Y.S. Lee, H.J. Kim, J.Y. Han, S.S. Im, H.K. Chong, J.K. Kwon, Y.H. Cho, W.K. Kim, T.F. Osborne, J.D. Horton, H.S. Jun, Y.H. Ahn, S.M. Ahn, and J.Y. Cha. 2011. Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. *PLoS One*. 6(7):e22544. PMCID: PMC3141076.
59. S. Sullivan, E. Fabbrini, J.D. Horton, K. Korenblat, B. Patterson, and S. Klein. 2011. Relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. *Trans. Res.* 158:302-306. PMCID: PMC3200562.
60. A.K. Agarwal, S. Sukumaran, V.A. Cortés, K. Tunison, D. Mizrachi, R. Gerard, K. Luby-Phelps, J.D. Horton, and A. Garg. 2011. Human AGPAT isoforms 1 and 2: Biochemical characterization and their inability to rescue hepatic steatosis in *Agpat2<sup>-/-</sup>* lipodystrophic mice. *J. Biol. Chem.* 286:37676-37691. PMCID: PMC3199511.
61. S. Shetty, M.A. Ramos-Roman, Y.R. Cho, J. Brown, J. Plutzky, E.S. Muise, J.D. Horton, P.E. Scherer, and E.J. Parks. 2012. Enhanced fatty acid flux triggered by adiponectin overexpression. *Endocrinology*. 153:113-122. PMCID: PMC3249680.
62. Y-A. Moon, G. Liang, X. Xie, M. Frank-Kamenetsky, K. Fitzgerald, V. Koteliansky, M.S. Brown, J.L. Goldstein, and J.D. Horton. 2012. The Scap/SREBP pathway in liver: Essential for diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. *Cell Metab.* 15:240-246. PMCID: PMC3662050.
63. D. Ai, C. Chen, S. Han, A. Ganda, A. Murphy, R. Haeusler, E. Thorp, D. Accili, J.D. Horton and A.R. Tall 2012. Regulation of hepatic LDL receptors by mTORC1 and PCSK9. *J. Clin. Invest.* 122: 1262-1270. PMCID: PMC3314476.
64. E. Fabbrini, P.B. Higgins, F. Magkos, R.A. Bastarrachea, V.S. Voruganti, A.G. Comuzzie, R.E. Shade, A. Gastaldelli, J.D. Horton, D. Omodei, B.W. Patterson, S. Klein. 2013. Metabolic response to high-carbohydrate and low-carbohydrate meals in a non-human primate model. *Am. J. Physiol. Endocrinol. Metab.* 304:E444-451. PMCID: PMC3566507.
65. Y. Deng, Z.V. Wang, C. Tao, N. Gao, W.L. Holland, A. Ferdous, J.J. Repa, G. Liang, J. Ye, M.A. Lehrman, J.A. Hill, J.D. Horton, P.E. Scherer. The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism. 2013. *J. Clin. Invest.* 123:455-468. PMCID: PMC3533268.
66. B. Ding, W. Wang, T. Selvakumar, H.S. Xi, H. Zhu, C.W. Chow, J.D. Horton, R.M. Gronostajski, D.L. Kilpatrick. 2013. Temporal regulation of Nuclear Factor One occupancy by calcineurin/NFAT governs a voltage-sensitive developmental switch in late maturing neurons. *J. Neurosci.* 33:2860-2872. PMCID: PMC3711774.

**Jay D. Horton, M.D.****Curriculum Vitae**

67. K. Fitzgerald, M. Frank-Kamenetsky, S. Shulga-Morskaya, A. Liebow, B.R. Bettencourt, J.E. Sutherland, R.M. Hutabarat, V.A. Clausen, V. Karsten, J. Cehelsky, S.V. Nochur, V. Kotelianski, J.D. Horton, T. Mant, J. Chiesa, J. Ritter, M. Munisamy, A.K. Vaishnav, J.A. Gollob, A. Simon. 2014. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. *Lancet.* 383:60-68. PMCID: PMC4387547.
68. V.A. Cortés, K.M. Cautivo, S. Rong, A. Garg, J.D. Horton, A.K. Agrawal. 2014. Leptin ameliorates insulin resistance and hepatic steatosis in *Agpat2*<sup>-/-</sup> lipodystrophic mice independent of hepatocyte leptin receptors. *J. Lipid Res.* 55:276-288. PMCID: PMC3886666.
69. S. Sankella, A. Garg, J.D. Horton, A.K. Agarwal. 2014. Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic *Agpat2*<sup>-/-</sup> mice. *J. Biol. Chem.* 289:4762-4777. PMCID: PMC3931038.
70. M. Xu, J.S. Nagati, J. Xie, J. Li, H. Walters, Y-A. Moon, R.D. Gerard, C.L. Huang, S.A. Comerford, R.E. Hammer, J.D. Horton, R. Chen, J.A. Garcia. 2014. An acetate switch regulates stress erythropoiesis. *Nat. Med.* 20:1018-1026. PMCID: PMC4159437.
71. J.A. Duarte, F. Carvalho, M. Pearson, J.D. Horton, J.D. Browning, J.G. Jones, S.C Burgess. 2014. A HFD suppresses de novo lipogenesis and desaturation, but not elongation and triglyceride synthesis in mice. *J. Lipid Res.* 55:2541-2553. PMCID: PMC4242447.
72. Y-A. Moon, C.R. Ochoa, M.A. Mitsche, R.E. Hammer, J.D. Horton. 2014. Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance. *J. Lipid Res.* 55:2597-2605. PMCID: PMC4242452.
73. S.A. Comerford, Z. Huang, X. Du, Y. Wang, L. Cai, A.K. Witkiewicz, H. Walters, M.N. Tantawy, A. Fu, H.C. Manning, J.D. Horton, R.E. Hammer, S.L. McKnight, B.P. Tu. 2014. Acetate dependence of tumors. *Cell.* 159:1591-602. PMCID: PMC4272450.
74. L. Goedeke, N. Rotllan, A. Canfran-Duque, J.F. Aranda, C.M. Ramirez, E. Araldi, C.S. Lin, N.N. Anderson, A. Wagschal, R. de Cabo, J.D. Horton, M.A. Lasuncion, A.M. Naar, Y. Suarez, C. Fernandez-Hernando. 2015. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. *Nat. Med.* 11:1280-1289. PMCID: PMC4711995.
75. P. Bartuzzi, D.D. Billadeau, R. Favier, S. Rong, D. Dekker, A. Fedoseienko, H. Fieten, M. Wijers, J.H. Levels, N. Huijkman, N. Kloosterhuis, H. van der Molen,

**Jay D. Horton, M.D.****Curriculum Vitae**

- G. Brufau, A.K. Groen, A.M. Elliott, J.A. Kuivenhoven, B. Plecko, G. Grangl, J. McGaughran, J.D. Horton, E. Burstein, M.H. Hofker, B. van de Sluis. 2016. CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. *Nat. Commun.* Mar 11;7:10961. PMCID: PMC4792963.
76. A.K. Agarwal, K. Tunison, J.S. Dalal, C.E. Yen CE, R.V. Farese, J.D. Horton, A. Garg. 2016. Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2<sup>-/-</sup>) or obese (ob/ob) mice. *J. Lipid Res.* 57:616-630. PMCID: PMC4808770.
77. K.M. Cautivo, P.J. Tapia, C.O. Lizama, A.K. Agarwal, A. Garg, J.D. Horton\*, and Víctor A. Cortés\*. 2016. AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. *Mol. Metab.* 5:491-505. PMCID: PMC27408775, PMID24708775.
78. K. Fitzgerald, S. White, A. Borodovsky, B.R. Bettencourt, A. Strahs, V. Clausen, P. Wijngaard, J.D. Horton, J. Taubel, A. Brooks, F. Chamikara, R.S. Kauffman, D. Kallend, A. Vaishnav, and A. Simon. 2017. A highly durable RNAi therapeutic inhibitor of PCSK9. *N. Engl. J. Med.* 376:41-51. PMCID: Not Required/Not NIH or participating funder's public access policy supported. PMID27959715.
79. H.A. Ferris, R.J. Perry, G.V. Moreira, G.I. Shulman, J.D. Horton, C.R. Kahn. 2017. Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism. *Proc. Natl. Acad. Sci. USA.* 114:1189-1194. PMCID: PMC5293102, PMID5293102.
80. S. Rong, V.A. Cortés, S. Rashid, N.N. Anderson, J.G. McDonald, G. Liang, Y-A. Moon, R.E. Hammer, J.D. Horton. 2017. Expression of SREBP-1c Requires SREBP-2-mediated generation of a sterol ligand for LXR in livers of mice. *Elife.* Feb 28;6. e25015. PMCID: PMC5348127, PMID28244871.
81. Y. Deng, Z.V. Wang, R. Gordillo, Y. An, C. Zhang, Q. Liang, J. Yoshino, K.M. Cautivo, J. De Brabander, J.K. Elmquist, J.D. Horton, J.A. Hill, S. Klein, P.E. Scherer. 2017. An adipo-biliary-uridine axis that regulates energy homeostasis. *Science.* 355(6330):eaaf5375. PMCID5832364, PMID28302796.
82. B.A. Ference, H.N. Ginsberg, I. Graham, K.K. Ray, C.J. Packard, E. Bruckert, R.A. Hegele, R.M. Krauss, F.J. Raal, H. Schunkert, G.F. Watts, J. Boren, S. Fazio, J.D. Horton, L. Masana, S.J. Nicholls, B.G. Nordestgaard, B. van de Sluis, M. R. Taskinen, L. Tokgozoglu, U. Landmesser, U. Laufs, O. Wiklund, J.K. Stock, M.J. Chapman, A.L. Catapano. 2017. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur. Heart J.* 24: doi: 10.1093. PMCID: PMC5832364.

**Jay D. Horton, M.D.****Curriculum Vitae**

83. J.M. Berger, A. Loza Valdes, J. Gromada, N. Anderson, J.D. Horton. 2017. Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice. *J. Lipid Res.* 58(8):1661-1669. PMC5538287.
84. C.W. Kim, C. Addy, J. Kusunoki, N.N. Anderson, S. Deja, X. Fu, S.C. Burgess, C. Li, M. Chakravarthy, S. Previs, S. Milstein, K. Fitzgerald, D.E. Kelley, J.D. Horton. 2017. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: A Bedside to Bench Investigation. *Cell Metab.* 26:394-406. PMCID: PMC5603267.
85. M. Zimmer, P. Bista, E. L. Benson, D.Y. Lee, F. Liu, D. Picarella, R.B. Vega, C.B. Vu, M. Yeager, M. Ding, G. Liang, J.D. Horton, R. Kleemann, T. Kooistra, M.C. Morrison, P.Y. Wielinga, J.C. Milne, M.R. Jirousek, A.J. Nichols. 2017. CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E<sup>3</sup>-Leiden mice. *Hepatol. Comm.* 1:311-325. PMCID: PMC5721391, PMID29404461.
86. A.G. Linden, S. Li, H.Y. Choi, F. Fang, M. Fukasawa, K. Uyeda, R.E. Hammer, J.D. Horton, L.J. Engelking, G. Liang. 2018. Interplay between ChREBP and SREBP-1c Coordinates Postprandial Glycolysis and Lipogenesis in Livers of Mice. *J. Lipid Res.* 3: 475-487. PMCID: PMC5832931, PMID29335275.
87. Y. Deng, Z.V. Wang, R. Gordillo, Y. Zhu, A. Ali, C. Zhang, X. Wang, M. Shao, Z. Zhang, P. Iyengar, R.K Gupta, J.D. Horton, J.A. Hill, P.E. Scherer. 2018. Xbp1s overexpression drives uridine production and reduces obesity. *Mol. Metab.* 11:1-17. PubMed PMID:29551634.
88. L. Jia, X. Chang, S. Qian, C. Liu, C. C. Lord, N. Ahmed, C.E. Lee, S. Lee, L. Gautron, M.C. Mitchell, J.D. Horton, P.E. Scherer, J.K. Elmquist. 2018. Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease. *Mol. Metab.* 14:121-129. Epub 2018/6/10.
89. C. Crewe, Y. Zhu, V.A. Paschoal, N. Joffin, A.L. Ghaben, R. Gordillo, D.Y. Oh, G. Lang, J.D. Horton, P.E. Scherer. 2019. SREBP-regulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1. *JCI Insight.* 4(15):e129397. PMCID: PMC6693888
90. J. Borén, M.J. Chapman, R.M. Krauss, C.J. Packard, J. Bentzon, C.J. Binder, M.J. Daemen, L.L. Demer, R.A. Hegele, S.J. Nicholls, B.G. Nordestgaard, G.F. Watts, E. Bruckert, S. Fazio, B.A. Ference, I. Graham, J.D. Horton, U. Landmesser, U. Laufs, L. Masana, G. Pasterkamp, F.J. Raal, K.K. Ray, H. Schunkert, M-R Taskinen, B. van de Sluis, O. Wiklund, L. Tokgozoglu, A.L. Catapano, H.N. Ginsberg. 2020. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 2. Pathophysiological, genetic and therapeutic insights. A Consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur. Heart J.* 41:2313-2330. PMCID: PMC7308544

**Jay D. Horton, M.D.****Curriculum Vitae**

91. M. Kim, C. Lee, D.Y. Seo, H. Jee, J.D. Horton, J. Park, P.E. Scherer. 2020. The impact of endotrophin on the progression of chronic liver disease. *Exp. Mol. Med.* 10:1766-1776. PMCID: PMC8080612
92. L. González-Hódar, J.G. McDonald, G. Vale, B.M. Thompson, A-M. Figueroa, P.J. Tapia, F. Robledo, A.K. Agarwal, A. Garg, J.D. Horton, V. Cortés. 2021. Decreased caveolae in AGPAT2 lacking adipocytes is independent of changes in cholesterol or sphingolipid levels: A whole cell and plasma membrane lipidomic analysis of adipogenesis. *Biochim. Biophys. Acta.* 1867(9):166167. PMID: 33989739
93. C.M. Castorena, A. Caron, N. J. Michael, N.I. Ahmed, A.G. Arnold, J. Lee, C.E. Lee, C. Limboy, A. S. Tinajero, M. Granier, S. Wang, J.D. Horton, W.L. Holland, S. Lee, C. Liu, T. Fujikawa, J.K. Elmquist. 2021. CB1Rs in VMH neurons regulate glucose homeostasis but not body weight. *Am. J. Physiol. Endocrinol. Metab.* 321:E146-E155. PMID: 34097543
94. X. Fu, S. Deja, J.A. Fletcher, N.N. Anderson, M Mizerska, G. Vale, J.D. Browning, J.D. Horton, J.G. McDonald, M.A. Mitsche, S.C. Burgess. 2021. Measurement of lipogenic flux by deuterium resolved mass spectrometry. *Nat. Comm.* 12:3756. PMCID: PMC8213799
95. S. Wang, Q. Zhu, G. Liang, T. Franks, M. Boucher, K.K. Bence, M. Lu, C.M. Castorena, S. Zhao, J.K. Elmquist, P.E. Scherer, J.D. Horton. 2021. Cannabinoid receptor-1 signaling in hepatocytes and stellate cells does not contribute to NAFLD. *J. Clin. Invest.* 131(22):e152242. PMCID: PMC8592555
96. P.B. Duell, F.K. Welty, M. Miller, A. Chait, G. Hammond, Z. Ahmad, D.E. Cohen, J.D. Horton, G.S. Pressman, P.P. Toth. 2022. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. *Arterioscler. Thromb. Vasc. Biol.* 42(6):e168-e185.
97. J.D. Haddad, J.P. Almandoz, V. Gomez, A.R. Schulman, J.D. Horton, J. Schelling, S.E. Messiah, M.S. Mathew, E.M. Marroquin, A. Tavakkoli. 2023. Endoscopic sleeve gastroplasty: A practice pattern survey. *Obes. Surg.* Aug;33(8):2434-2442. Epub 2023 Jun 20. PMID: 37338795.
98. A.K. Agarwal, K. Tunison, G. Vale, J.G. McDonald, X. Li, P.E. Scherer, J.D. Horton, A. Garg. 2023. Regulated adipose tissue-specific expression of human *AGPAT2* in lipodystrophic *Agpat2*-null mice results in regeneration of adipose tissue. *iScience.* Sep 1; 26(10): 107806. eCollection 2023 Oct 20. PMID: 37752957.
99. S. Rong, M. Xia, G. Vale, S. Wang, C.W. Kim, L. Shili, J.G. McDonald, A. Radhakrishnan, J.D. Horton. 2024. Diacylglycerol acyltransferase 2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the endoplasmic reticulum. *Cell Metab.* 36:617-629. PMID: 38340721. PMCID: PMC10939742

**Jay D. Horton, M.D.**  
**Curriculum Vitae**

100. A.K. Agarwal, K. Tunison, G. Vale, J.G. McDonald, X. Li , J.D. Horton, A. Garg. 2024. Adipose-specific overexpression of human AGPAT2 in mice causes increased adiposity and mild hepatic dysfunction. *iScience*. 2023 Dec 7;27(1):108653. doi: 10.1016/j.isci.2023.108653. eCollection 2024 Jan 19. PMID: 38274405.
101. S. Deja , J.A. Fletcher, C.-W. Kim , B. Kucejova , X. Fu , M. Mizerska , M. Villegas , N. Pudelko-Malik , N. Browder, M. Inigo-Vollmer, C.J. Menezes, P. Mishra, E.D. Berglund, J.D. Browning, J.P. Thyfault , J.D. Young , J.D. Horton\*, S.C. Burgess\*. 2024. Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability. *Cell Metab*. 36(5):1088-1104. PMCID: PMC11081827
102. A. K. Agarwal, K. Tunison, J.D. Horton, A. Garg. 2024. Regulated regeneration of adipose tissue in lipodystrophic *Agpat2*-null mice partially ameliorates hepatic steatosis. *iScience*. 2024. Mar 26;27(4):109517. doi: 10.1016/j.isci.2024.109517. eCollection 2024 Apr 19. PMID: 38623324.
103. A. Elnwasany, H.A. Ewida, I. Menendez-Montes, M. Mizerska, X. Fu, C.-W. Kim , J.D. Horton, S.C. Burgess, B.A. Rothermel, P.A. Szweda, L.I. Szweda. 2024. Reciprocal regulation of cardiac b-oxidation and pyruvate dehydrogenase by insulin. *J Biol Chem*. May 23;107412. doi: 10.1016/j.jbc.2024.107412. Online ahead of print.

**INVITED REVIEWS /COMMENTARIES**

104. J.D. Horton and I. Shimomura. 1999. SREBPs: Activators of cholesterol and fatty acid biosynthesis. *Curr. Opin. Lipidol*. 10:143-150.
105. J.D. Horton, J.L. Goldstein, and M.S. Brown. 2002. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in liver. *J. Clin. Invest*. 109:1125-1131.
106. J.D. Horton. 2002. SREBPs: Transcriptional activators of lipid synthesis. *Biochemical Society Transactions*: Vol. 30. 1091-1095.
107. J.D. Horton, J.L. Goldstein, and M.S. Brown. 2002. SREBPs: Transcriptional mediators of lipid homeostasis. In **Cold Spring Harbor Symposium on Quantitative Biology: The Cardiovascular System, Volume 67**. 491-498.
108. J.D. Browning and J.D. Horton. 2003. Gallstone disease and its complications. *Seminars in Gastroenterology*. 14:165-177.
109. J.D. Browning and J.D. Horton. 2004. Molecular mediators of hepatic steatosis and liver injury. *J. Clin. Invest*. 114:147-152.
110. J.D. Horton, J.C. Cohen, and H.H. Hobbs. 2007. Molecular biology of PCSK9: role in LDL metabolism. *Trends Biochem. Sci*. 2:71-77.

## **Jay D. Horton, M.D.**

### **Curriculum Vitae**

111. J.D. Horton. 2008. Unfolding lipid metabolism. *Science*. 320:1433-1434. PMCID: PMC2701207.
112. J.D. Horton. J.C. Cohen, and H.H. Hobbs. 2009. PCSK9: a convertase that coordinates LDL catabolism. *J. Lipid Res.* 50: Suppl:S172-177. PMCID: PMC2674748.
113. J.C. Cohen, J.D. Horton, H.H. Hobbs. 2011. Human fatty liver disease: Old questions and new insights. *Science*. 332:1519-23.
114. R.A. Debose-Boyd and J.D. Horton. 2013. Opening up new fronts in the fight against cholesterol. *Elife*. Apr 9;2:e00663.
115. J.D. Horton. 2019. Intravascular triglyceride lipolysis becomes crystal clear. *Proc. Natl. Acad. Sci. USA*. 116:1480-1482.
116. R.A. Hegele, J.W. Knowles, J.D. Horton. 2020. Delisting *STAP1*: The rise and fall of a putative hypercholesterolemia gene. *Arterioscler. Thromb. Vasc. Biol.* 40:847-849. Epub 2020 Mar 25.
117. S.D. Turley, J.D. Horton, J.M. Andersen, and J.S. Fordtran. 2021. In Memoriam: John M. Dietschy Sr., MD (1932-2020). *J. Lipid Res.* 62:100015.
118. H.H. Hobbs, J.C. Cohen, J.D. Horton. 2024. PCSK9: From nature's loss to patient's gain. *Circulation*. 149(3):171-173. PMCID: PMC10874118

## **CHAPTERS**

119. J.D. Horton: Esophagus, Small and Large Intestine Sections 3 and 5. **In Gastrointestinal Disease Review and Assessment**. Edited by R.A. Weisiger and L. Bilhartz. 1996. W.B. Saunders Co., Philadelphia.
120. L.E. Bilhartz and J.D. Horton: Gallstone disease and its complications. Chapter 55. **In Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management**. Edited by M. Feldman, B.F. Scharschmidt and M.H. Sleisenger. 6<sup>th</sup> edition. 1997. W.B. Saunders Co., Philadelphia.
121. J.D. Horton: Sterol regulatory element-binding proteins. **In Wiley Encyclopedia of Molecular Medicine**. Vol. 5:3022-3025. 2002. John Wiley & Sons, Inc., Colorado Springs.
122. J.D. Horton and L.E. Bilhartz: Gallstone disease and its complications. Chapter 55. **In Sleisenger & Fordtran's Gastrointestinal and Liver Disease**. Edited by M. Feldman, L.S. Friedman and M.H. Sleisenger. 7<sup>th</sup> edition. 2002. W.B. Saunders Co., Philadelphia.

## **Jay D. Horton, M.D.**

### **Curriculum Vitae**

123. J.E. Elmquist and J.D. Horton: Control of appetite/satiety and energy balance. Chapter 28. **In Yamada's Textbook of Gastroenterology.** Edited by D.K Podolsky, M. Camilleri, J.G. Fitz, A.N. Kalloo, F. Shanahan, T.C. Wang. 6<sup>th</sup> edition. 2015. Wiley-Blackwell, Hoboken, NJ.

### **PATENTS**

1. US 7,737,266 B2 "**RNAI Modulation of SCAP and Therapeutic Uses Thereof**"  
Inventors: Pamela Tan Juergen Soutschek Jay D. Horton Michael S. Brown Joseph L. Goldstein Young-Ah Moon  
Patent Issued: 4/5/2011  
Patent Number: 7919613
2. "**Cell-Based PCSK9 Screening Assay**"  
Inventors: Jay D. Horton Markey C. McNutt  
Agents: CHALKER FLORES, LLP  
Assignees: Board of Regents, The University of Texas System  
Origin: DALLAS, TX US  
IPC8 Class: AG01N3353FI  
USPC Class: 435 76  
Patent application number: 20090275053

### **RESEARCH SUPPORT**

P01 HL160487, Horton (PI) 01/1/2022-12/31/2026

New Approaches to Reduce Residual Cardiovascular Risk

Role: PI of PPG and Project 2

P30DK127984-01, Horton (PI) 06/01/2022-05/31/2027

UT Southwestern NORC

Role: PI

### **MEMBERSHIPS**

1. American College of Physicians
2. Texas Medical Association
3. Dallas County Medical Society
4. American Gastroenterological Association
5. American Association for the Study of Liver Diseases
7. American Society for Biochemistry and Molecular Biology
8. American Society for Clinical Investigation
9. Association of American Physicians